[{"id":"6b26b0df-c972-4fed-adba-6edb4b098b89","acronym":"KEYNOTE-D88","url":"https://clinicaltrials.gov/study/NCT05572684","created_at":"2022-10-10T15:07:08.123Z","updated_at":"2025-02-25T16:18:14.094Z","phase":"Phase 1/2","brief_title":"A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors","source_id_and_acronym":"NCT05572684 - KEYNOTE-D88","lead_sponsor":"NextCure, Inc.","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • NC410"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 10/06/2022","start_date":" 10/06/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-12-16"}]